Сахар из можжевеловой ягоды: [брошюра]

0|3|Сахар из можжевеловой ягоды [c. 3]0|7|Инструкция по сбору, сушке и хранению можжевеловой ягоды [c. 7]0|8|Инструкция по переработке можжевеловой ягоды на сладкие экстракты и сироп для школ, госпиталей, столовых и домашнего быта [c. 8]0|11|Использование экстракта и сиропа [c. 11

Worst case type I error for various choices of weights and information fractions.

<p>Nominal level <i>α</i> = 0.025 one-sided.</p

Schematic of a two-stage adaptive trial design with delayed response using the independent increments assumption.

<p>Schematic of a two-stage adaptive trial design with delayed response using the independent increments assumption.</p

Trade-off involved in choosing between methods when extending the follow-up period of a survival trial.

<p>Methods considered: (A), data is combined assuming independent stage-wise increments; (B), patient-wise separation with pre-fixed end of first-stage follow-up; (C), naive patient-wise separation without pre-fixed end of first-stage follow-up; and (D), patient-wise separation using the full-data guaranteed level-<i>α</i> test.</p

Schematic of a two-stage adaptive trial design with delayed response using patient-wise separation.

<p>Schematic of a two-stage adaptive trial design with delayed response using patient-wise separation.</p

Supplemental material for A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay

<p>Supplemental material for A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay by Eleni Vradi, Thomas Jaki, Richardus Vonk and Werner Brannath in Statistical Methods in Medical Research</p

Additional file 1 of Tilting the lasso by knowledge-based post-processing

More simulation results and interpretations in Appendix A and Appendix B. R-code for data is presented in Appendix C. (PDF 141 kb

Development of a CONSORT Extension for adaptive clinical trials

<p>The ACE Project aims to develop a consensus-driven reporting guidance tailored for ADs in the form of a CONSORT extension. We hope this will enhance transparency, credibility, reproducibility, and replicability of adaptive trials. The hope would be to facilitate uptake of ADs in clinical trials research when appropriate.</p><p>The ACE Project is jointly funded by the NIHR and MRC HTMR, and is led by a multidisciplinary Steering Working Group of international experts in collaboration with the CONSORT Executive Group and the MRC HTMR Adaptive Designs Working Group</p